Elite in Alpha-1 Antitrypsin Deficiency (AATD)

Pavel Strnad

Albert Einstein Allee 23, 
Ulm, BW, DE 
Elite in Alpha-1 Antitrypsin Deficiency (AATD)
Albert Einstein Allee 23, 
Ulm, BW, DE 
OverviewLocationsClinical Research

Overview

Pavel Strnad practices in Ulm, Germany. Mr. Strnad is rated as an Elite expert by MediFind in the treatment of Alpha-1 Antitrypsin Deficiency (AATD). His top areas of expertise are Subcutaneous Emphysema, Alpha-1 Antitrypsin Deficiency (AATD), Emphysema, Liver Transplant, and Hepatectomy.

His clinical research consists of co-authoring 171 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 31 articles and participated in 3 clinical trials in the study of Alpha-1 Antitrypsin Deficiency (AATD).

Gender
Male

Locations

Albert Einstein Allee 23, Ulm, BW 89081, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Pilot Open Label, Multi-dose, Phase 2 Study to Assess the Safety and Efficacy of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)
A Pilot Open Label, Multi-dose, Phase 2 Study to Assess the Safety and Efficacy of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Placebo-Controlled, Multi-dose, Phase 2 Study to Determine the Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency (AATD) [SEQUOIA]
A Placebo-Controlled, Multi-dose, Phase 2 Study to Determine the Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency (AATD) [SEQUOIA]
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Other, Drug
Study Drug: ARO-AAT
Study Phase: Phase 2
A Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-814 in PiZZ Subjects
A Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-814 in PiZZ Subjects
Enrollment Status: Terminated
Publish Date: February 02, 2022
Intervention Type: Drug
Study Phase: Phase 2
Predicting Acute-on-Chronic Liver Failure in Cirrhosis (PREDICT) Study
Predicting Acute-on-Chronic Liver Failure in Cirrhosis (PREDICT) Study
Enrollment Status: Completed
Publish Date: April 12, 2019
Intervention Type: Other
View 3 Less Clinical Trials

171 Total Publications

Performance of enhanced liver fibrosis test and indirect serum fibrosis markers for exclusion of advanced liver fibrosis in alpha-1 antitrypsin deficiency.
Performance of enhanced liver fibrosis test and indirect serum fibrosis markers for exclusion of advanced liver fibrosis in alpha-1 antitrypsin deficiency.
Journal: European journal of internal medicine
Published: April 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Strnad's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 30 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile